Table 1 Characteristics of studies included in this systematic review and meta-analysis
Author | Country | Study period (months) | Drug regimen | No. of participants | Genotype | Adverse events (%) | Patients with detectable parasitaemia and/or malaria clinical episodes (%) | No. of deaths | Success rate (95% CI) |
|---|---|---|---|---|---|---|---|---|---|
Olaosebikan et al., 2015 | Nigeria | 14 | MQAS | 90 | SS/SC | 24 | 7.78 | 4 | 61% (compared to PG) |
SPAQ | 90 | 13.8 | 13.33 | 0 | 36% (compared to PG) | ||||
PG | 90 | 5.4 | 21.11 | 3 | – | ||||
Diop et al., 2010 | Senegal | 6 | PL | 30 | SS | 3.33 | 13.33 | 0 | 86.67% |
SP | 30 | 3.33 | 0 | 0 | 100% | ||||
Nakibuuka et al., 2009 | Uganda | 5 | SP | 120 | SS | 6.6 and 1.6 (vomiting, Pruritus) | 14 | 0 | 50% (compared to CQ) |
CQ | 122 | 11.5 and 1.8 (vomiting, Pruritus) | 24.6 | 0 | – | ||||
Eke et al., 2003 | Nigeria | 9 | PL | 30 | SS | Not reported | 31 | 1 | 69% |
PM | 36 | 38.9 | 0 | 61% | |||||
PG | 35 | 15.6 | 0 | 84% | |||||
Nwokolo et al., 2001 | Nigeria | 6 | PG | 57 | SS | 19.6 | 18.2 | None | 81.80% |
MQ | 56 | 31.6 | 10.8 | None | 89.20% | ||||
Warley et al., 1965 | Uganda | 21 | PL | 66 | SS | NA | 31.82 | None | 68.18 |
CQ + benzathine penicillin | 60 | NA | 11.67 | None | 88.33 |